Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ·
Trial Information
Current as of September 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how advanced genetic testing, called genomic sequencing, can help improve care for cancer patients. Using two special platforms named SeqOIA and AURAGEN, the study looks at how this testing affects treatment decisions, the speed of getting results, and how well patients are informed about their care. The goal is to understand the benefits and challenges of using this technology so healthcare providers can plan better cancer care in the future.
Anyone with cancer might be eligible to join, as the study is open to all adults regardless of gender. Participants can expect their tumor samples to be tested using these genomic platforms, and their medical information will be reviewed to see how the test results influence their treatment. This study is also helping doctors and public health officials decide how to best use genetic testing to support patients nationwide.
Gender
ALL
Eligibility criteria
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Isabelle DURAND-ZALESKI, Professor
Principal Investigator
Greater Paris University Hospitals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported